Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager

Fineline Cube Jun 22, 2026
Company Deals

CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player

Fineline Cube Jun 22, 2026
Company Deals

Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer

Fineline Cube Jun 22, 2026
Company Deals

Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners

Fineline Cube Jun 22, 2026
Company Deals

Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases

Fineline Cube Jun 22, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio

Fineline Cube Jun 22, 2026
Company Drug

Mabwell Bioscience Presents Promising Phase I/II Data for Nectin-4 ADC Bulumtatug Fuvedotin in Cervical Cancer at ESMO-GC

Fineline Cube Jun 22, 2026
Company Drug

Yantai Dongcheng Pharmaceutical’s 18F-LNC1007 Receives Clinical Clearance for Solid Tumor Diagnostics

Fineline Cube Sep 23, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has received clinical...

Company Drug

Fosun Pharmaceutical’s PD-1 Inhibitor HanSiZhuang Recommended for Approval by EMA’s CHMP

Fineline Cube Sep 23, 2024

Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196), a leading pharmaceutical company in...

Company Deals

Tencent’s We Doctor Partners with CHA on National Digital Health Platform and Academic Initiatives

Fineline Cube Sep 23, 2024

We Doctor, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700) specializing...

Company Deals

Huadong Medicine Secures Exclusive Rights to Janagliflozin for Type 2 Diabetes Treatment in China

Fineline Cube Sep 23, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing...

Policy / Regulatory

Beijing Aims to Establish Rare Disease Drug Security Pilot Zone with ‘White List’ System

Fineline Cube Sep 23, 2024

Beijing is set to follow in the footsteps of Boao Lecheng with the release of...

Policy / Regulatory

Beijing Authorities Release Negative List for Data Export in Key Industries

Fineline Cube Sep 23, 2024

Authorities in Beijing, including the Beijing Municipal Bureau of Commerce and the Beijing Municipal Service...

Company Drug

AstraZeneca’s HIMALAYA Trial Data Showcases Significant Survival Benefits for Liver Cancer Treatment at ESMO 2024

Fineline Cube Sep 22, 2024

At the European Society for Medical Oncology (ESMO) 2024 conference, AstraZeneca (NASDAQ: AZN, LON: AZN)...

Company Drug

Aligos Therapeutics’ ALG-055009 Achieves Positive Topline Results in Phase 2a HERALD Study for MASH

Fineline Cube Sep 21, 2024

Aligos Therapeutics, a clinical-stage biopharmaceutical company focused on liver and viral diseases, has announced positive...

Company Drug

Roche’s Xofluza Receives FDA Approval for Reducing Influenza Transmission in Phase III Study

Fineline Cube Sep 21, 2024

Roche (SWX: ROG; OTCMKTS: RHHBY) has announced that its antiviral drug Xofluza (baloxavir marboxil) has...

Company Drug

J&J’s Rybrevant Secures FDA Approval for EGFR/c-MET Non-Small Cell Lung Cancer Treatment

Fineline Cube Sep 21, 2024

Johnson & Johnson (J&J; NYSE: JNJ)has announced that the US Food and Drug Administration (FDA)...

Company Drug

Beijing’s Apollobio Receives NMPA Approval for HPV Therapeutic Vaccine VGX-3100

Fineline Cube Sep 21, 2024

Beijing’s Apollobio, has announced that the National Medical Products Administration (NMPA) has granted market approval...

Company Drug

Insilico Medicine’s AI-Generated Drug Candidate ISM001-055 Shows Positive Phase II Results in IPF Study

Fineline Cube Sep 20, 2024

China-based artificial intelligence (AI) drug developer Insilico Medicine has reported initial positive data from its...

Company Drug

Lee’s Pharmaceutical’s Zhaoke Ophthalmology Receives NMPA Approval for Generic Lumigan

Fineline Cube Sep 20, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622), has...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ SHR-1701 Combo Therapy for Gastric Cancer Accepted for Review by China’s NMPA

Fineline Cube Sep 20, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

JiCui Cell Therapy Forms Partnership with Fosun Kite to Advance Bispecific CAR-T Cell Therapy Industrialization

Fineline Cube Sep 20, 2024

JiCui Cell Therapy Drug Research Institute, also known as Jiangsu Jicui Juechuang Biotechnology Research Institute...

Company Deals

Apeloa Pharmaceutical Invests in Ji Xing Pharmaceuticals’ Series D Financing Round

Fineline Cube Sep 20, 2024

China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced its participation in the Series D...

Company

CSPC Pharmaceutical Group Appoints Dr. Liu Yongjun as Group CEO and Global R&D President

Fineline Cube Sep 20, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company

Sinopharm Holding Appoints New Chairman and President Following Leadership Changes

Fineline Cube Sep 20, 2024

Sinopharm Holding (HKG: 1099) has announced significant changes in its leadership with the approval of...

Medical Device Policy / Regulatory

China’s NMPA Releases Standards for Brain-Computer Interface Medical Devices

Fineline Cube Sep 20, 2024

The National Medical Products Administration (NMPA) in China has issued a notification confirming the establishment...

Company

Sichuan Kelun-Biotech Reports 32.2% Revenue Growth in 2024 H1, Driven by MSD Partnership

Fineline Cube Sep 20, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced its financial results for the first...

Posts pagination

1 … 315 316 317 … 686

Recent updates

  • Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager
  • CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player
  • Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer
  • Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio
  • Mabwell Bioscience Presents Promising Phase I/II Data for Nectin-4 ADC Bulumtatug Fuvedotin in Cervical Cancer at ESMO-GC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager

Company Deals

CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player

Company Deals

Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer

Company Drug

Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.